Ireland
--:--IST
Latest
Clinical Trials in the USA / NCT07821697
Starting soon Phase EARLY_PHASE1

Translational Recording and Characterization of Epilepsy Signals Using Subgaleal EEG During Standard-of-care SEEG Monitoring

NCT07821697 · tracked via the Priya Life Science USA tracker
Sponsor
Adraxe Corp
Phase
Phase EARLY_PHASE1
Started
2026-10-15
Last updated
2026-09-16

Condition(s) studied

Epilepsy (Treatment Refractory)

Investigational drug(s) / intervention(s)

EEG Record only

EEG Record only: Subgaleal EEG recording

Study summary

TRACE is a record-only study evaluating subgaleal EEG (sgEEG) recorded concurrently with standard-of-care stereoelectroencephalography (SEEG) in adults with drug-resistant epilepsy undergoing inpatient epilepsy monitoring. The study will assess the ability of sgEEG to detect seizures and characterize seizure timing, signal quality and stability, and lateralization compared with SEEG.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 years or older. * Diagnosis of drug-resistant epilepsy. * Scheduled to undergo clinically indicated inpatient standard-of-care stereoelectroencephalography (SEEG) monitoring. * Able and willing to provide written informed consent. * In the investigator's judgment, able to comply with study procedures. Exclusion Criteria: * Any medical, neurological, psychiatric, or social condition that, in the investigator's judgment, would make participation unsafe or interfere with study procedures or data interpretation. * Active infection, skin condition, or other finding at the planned subgaleal electrode placement site that could increase procedural risk. * Known bleeding disorder, clinically significant coagulopathy, or use of anticoagulant/antiplatelet therapy that cannot be managed per institutional requirements for the planned procedure. * Pregnancy or breastfeeding. * Participation in another investigational study that, in the investigator's judgment, could interfere with TRACE procedures or outcomes.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Minnisota Minneapolis Minnesota

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07821697 on ClinicalTrials.gov ↗ ← All trials in the USA